<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1999">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734678</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-Infliximab</org_study_id>
    <nct_id>NCT04734678</nct_id>
  </id_info>
  <brief_title>Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome</brief_title>
  <official_title>Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Misr International University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the end of 2019, Egypt and the whole world have been suffering from the Coronavirus&#xD;
      Disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome&#xD;
      coronavirus 2 (SARS-CoV-2). According to the World Health Organization (WHO), since the&#xD;
      emergence of this new pandemic, there have been more than 97 million confirmed cases of&#xD;
      COVID-19 patients and two million death globally; around 160 thousand of these cases are in&#xD;
      Egypt.&#xD;
&#xD;
      Tocilizumab play role among the unique therapeutic alternatives for the management of&#xD;
      cytokine release syndrome (CRS), a life-threatening complication of chimeric antigen receptor&#xD;
      (CAR) - T cell therapy. CRS occurs as a result of uncontrolled immune activation with release&#xD;
      of pro-inflammatory cytokines and chemokines. Up till now, clinical trial and expertise with&#xD;
      tocilizumab in COVID-19 patients has been limited. Despite preliminary encouraging results,&#xD;
      recent studies suffered from limitations such as the absence of consistent treatment outline,&#xD;
      a short post-treatment follow-up, and the absence of a comparison group.&#xD;
&#xD;
      A recent study discussed the possible beneficial effect of tumor necrosis factor (TNF)&#xD;
      inhibitors in severe COVID-19. Specifically, TNF may aggravate lymphopenia through direct&#xD;
      killing via TNF/TNFR1 signaling in T cells, and T cell dysfunction reveals an important yet&#xD;
      underestimated target for immunomodulatory therapeutic approaches. Accordingly, anti-TNF may&#xD;
      be considered as an encouraging therapeutic option in severe COVID-19.&#xD;
&#xD;
      These promising clinical findings encouraged us to use infliximab (IFX), a chimeric&#xD;
      monoclonal anti-TNF antibody, as an experimental therapy in patients with moderate and severe&#xD;
      COVID-19 in the absence of IBD.&#xD;
&#xD;
      In this study, we compare the outcomes of a large cohort of patients with moderate and severe&#xD;
      COVID-19 pneumonia treated with tocilizumab in addition to standard management, with those of&#xD;
      concomitantly hospitalized patients who received infliximab and tocilizumab in addition to&#xD;
      standard management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients' clinical status improvement using six category scale</measure>
    <time_frame>Two weeks</time_frame>
    <description>The categories were defined as follows: 1) patient discharged, 2) hospitalization not requiring supplemental oxygen, 3) hospitalization requiring supplemental low-flow oxygen, 4) hospitalization requiring high-flow supplemental oxygen, 5) hospitalization requiring invasive mechanical ventilation, 6) death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to improvement in oxygenation</measure>
    <time_frame>48 hours</time_frame>
    <description>Increase in SpO2/FiO2 of 50 or greater compared to the baseline SpO2/FiO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Two weeks</time_frame>
    <description>Total admission period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Two weeks</time_frame>
    <description>Death during hospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-invasive mechanical ventilation</measure>
    <time_frame>Two weeks</time_frame>
    <description>Need for non-invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of non-invasive mechanical ventilation</measure>
    <time_frame>Two weeks</time_frame>
    <description>Time required for non-invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of invasive mechanical ventilation</measure>
    <time_frame>Two weeks</time_frame>
    <description>Need for invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of invasive mechanical ventilation</measure>
    <time_frame>Two weeks</time_frame>
    <description>Time required for invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Secondary infections</measure>
    <time_frame>Two weeks</time_frame>
    <description>Especially Sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of adverse events</measure>
    <time_frame>Two weeks</time_frame>
    <description>Monitoring of adverse events especially elevation of liver enzymes daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of cardiovascular events</measure>
    <time_frame>Two weeks</time_frame>
    <description>Prevalence of heart failure, tachycardia and hypertension</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Covid19</condition>
  <condition>Cytokine Storm</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with tocilizumab in addition to standard management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Moderate and severe patients who were infected with SARS-CoV-2 and received treatment with infliximab and tocilizumab in addition to standard management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>400 mg IV only once</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>5 mg/kg/day IV for 2 doses 12-24 hours</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients received the same background treatment for 5 days, following an Institutional&#xD;
        protocol for standard of care: hydroxychloroquine 400 mg daily, lopinavir/ritonavir 400/100&#xD;
        mg twice daily or/and remdisivir 200 mg LD then 100 once daily as a maintenance dose and&#xD;
        anti-coagulation prophylaxis with enoxaparin subcutaneously once a day if D-dimmer between&#xD;
        500-1000 or enoxaparin therapeutic subcutaneously twice daily if D-dimmer &gt;1000.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-65 years.&#xD;
&#xD;
          2. Able to provide informed consent.&#xD;
&#xD;
          3. Patients hospitalized with pneumonia proved by chest X-ray or CT scan.&#xD;
&#xD;
          4. Confirmed infection with COVID-2019 using RT-PCR or strongly suspected to be infected&#xD;
             with pending confirmation studies.&#xD;
&#xD;
          5. Hyper-inflammation defined as elevation in either C-reactive protein (CRP, ≥ 100 mg/L,&#xD;
             normal values &lt;6 mg/L) or ferritin (≥ 900 ng/mL, normal value &lt;400 ng/mL), in the&#xD;
             presence of increased lactate dehydrogenase (LDH, &gt;220 U/L).&#xD;
&#xD;
          6. And at least one of the following:&#xD;
&#xD;
               1. Respiratory frequency ≥30/min.&#xD;
&#xD;
               2. Blood oxygen saturation ≤93% on room air (RA).&#xD;
&#xD;
               3. Partial pressure of arterial oxygen to fraction of inspired oxygen ratio&#xD;
                  (PaO2/FiO2) &lt;300 [18].&#xD;
&#xD;
               4. Worsening of lung involvement, defined as an increase in number and/or extension&#xD;
                  of pulmonary areas of consolidation, need for increased FiO2 to maintain stable&#xD;
                  O2 saturation, or worsening O2 saturation of &gt;3% with stable FiO2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of concomitant bacterial infection.&#xD;
&#xD;
          2. Concomitant use of other immunosuppressive biologic drugs.&#xD;
&#xD;
          3. Baseline elevation of alanine aminotransferase (ALT) or aspartate aminotransferase&#xD;
             (AST) levels &gt; 5-fold the upper limit of the normal range.&#xD;
&#xD;
          4. Pregnancy.&#xD;
&#xD;
          5. Treatment with any TNFα inhibitor in the past 30 days.&#xD;
&#xD;
          6. Known hypersensitivity to any TNFα inhibitor, murine proteins, or any component of the&#xD;
             formulation.&#xD;
&#xD;
          7. Known or suspected active tuberculosis (TB) or a history of incompletely treated or&#xD;
             latent TB.&#xD;
&#xD;
          8. Serious co-morbidity, including:&#xD;
&#xD;
               1. Myocardial infarction (within last month).&#xD;
&#xD;
               2. Moderate or severe heart failure (New York Heart Association (NYHA) class III or&#xD;
                  IV).&#xD;
&#xD;
               3. Hepatic patients child Pugh class C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Neven Sarhan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Misr International University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neven Sarhan, PhD</last_name>
    <phone>01021944422</phone>
    <email>sarhanneven@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mona farag Schaalan, PhD</last_name>
    <email>mona.schaalan@miuegypt.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Teachers Hospital</name>
      <address>
        <city>Cairo</city>
        <state>Please Select</state>
        <zip>11314</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neven Sarhan, PhD</last_name>
      <phone>01021944422</phone>
      <email>sarhanneven@gmail.com</email>
    </contact>
    <contact_backup>
      <phone_ext>Sarhan</phone_ext>
      <email>sarhanneven@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Neven M. Sarhan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mona F Schaalan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shery Fathy, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Essam, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Misr International University</investigator_affiliation>
    <investigator_full_name>Neven Sarhan</investigator_full_name>
    <investigator_title>Lecturer at Faculty of Pharmacy</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Cytokine Storm</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>Infliximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

